Pharmaceutical company Galderma has released data that suggest the sequence of injectable treatments may influence skin-quality outcomes in menopausal women.
An eight-month investigator-initiated trial, led by plastic surgeon Mr Andreas Nikolis and supported by Galderma, assessed two treatment sequences across the face and décolletage. Participants received either a hyaluronic acid skin booster (Restylane Skinboosters) before a poly-L-lactic acid collagen stimulator (Sculptra), or the reverse sequence.
According to the study findings, the skin-booster-first protocol produced an earlier visible response and greater dermal remodelling. In a survey of 5,090 women in the UK, US, Brazil and China, facial dermal thickness increased by 27.3% in this group, compared with 15.7% among those receiving the collagen stimulator first. Both sequences were associated with improvements in hydration and patient-reported satisfaction.
Anne-Cécile Chevrier, global head for injectable aesthetics at Galderma, commented, “Our research shows the scale of this knowledge gap and the need to move beyond a one-size-fits-all ageing narrative. At Galderma, we are committed to advancing the understanding of menopausal skin and providing women with clear, trusted information and science-backed solutions, so they can make informed choices and feel confident in their skin throughout this important stage of life.”